keyword
MENU ▼
Read by QxMD icon Read
search

Alendronate

keyword
https://www.readbyqxmd.com/read/29025668/sustained-raloxifene-release-from-hyaluronan-alendronate-functionalized-titanium-nanotube-arrays-capable-of-enhancing-osseointegration-in-osteoporotic-rabbits
#1
Caiyun Mu, Yan Hu, Ling Huang, Xinkun Shen, Menghuan Li, Liqi Li, Hao Gu, Yonglin Yu, Zhining Xia, Kaiyong Cai
To enhance the localized bone remodeling at titanium-based implants under osteoporotic conditions, TiO2 nanotube arrays (TNT) were used as nanoreserviors for raloxifene (Ral) and then covered with the hybrid multilayered coating of chitosan and alendronate grafted hyaluronic acid (HA-Aln) via a spin-assisted layer-by-layer technique. The fabrication of this system (TNT/Ral/LBL-Aln) was characterized by field emission scanning electron microscopy (SEM), atomic force microscope (AFM) and X-ray photoelectron spectroscopy (XPS), respectively...
January 1, 2018: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/29019595/effects-of-local-alendronate-administration-on-bone-defect-healing-histomorphometric-and-radiological-evaluation-in-a-rabbit-model
#2
Taha Özer, Alper Akta, Emre Barı, Hakan Hamdi Çelik, Alper Vatansever
PURPOSE: To performed a histomorphometric and radiological study to evaluate the effects of alendronate sodium administered locally in mandibular bone defects created in rabbits. METHODS: Two circular defects 5 mm in diameter were created bilaterally in the mandibular corpus of 20 New Zealand rabbits (i.e., four defects per animal). Each defect received one of four treatments: no treatment (EC group), alendronate irrigation (AL group), autogenous bone grafting (AG group), or alendronate irrigation with autogenous bone grafting (AL+AG group)...
September 2017: Acta Cirúrgica Brasileira
https://www.readbyqxmd.com/read/28994250/synthesis-and-evaluation-of-a-novel-99m-tc-nitrido-radiopharmaceutical-with-alendronate-dithiocarbamate-as-a-potential-bone-imaging-agent
#3
Xiaoqing Song, Yue Wang, Junbo Zhang, Zhonghui Jin, Weifang Zhang, Yanyan Zhang
Currently, a popular strategy for designing novel radioprobes as bone imaging agents is based on the concept of bifunctional radiopharmaceticals. Considering the dithiocarbamate ligand can act as a suitable bifunctional linking agent to attach technetium-99m ((99m) Tc) to corresponding target molecules, in this study, alendronate dithiocarbamate (ALNDTC) was synthesized and radiolabeled with [(99m) Tc≡N](2+) core by ligand-exchange reaction to produce (99m) TcN-ALNDTC complex, for the potential use as a novel probe for bone imaging...
October 10, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28986297/spray-congealed-solid-lipid-microparticles-as-a-new-tool-for-the-controlled-release-of-bisphosphonates-from-a-calcium-phosphate-bone-cement
#4
Luisa Stella Dolci, Silvia Panzavolta, Beatrice Albertini, Barbara Campisi, Massimo Gandolfi, Adriana Bigi, Nadia Passerini
The aim of this work was to develop an innovative drug delivery system potentially useful for the local delivery of Bisphosphonates to bone tissue. We propose the use of Solid Lipid Microparticles (MPs), up to now mainly used for oral and topical drug delivery, as carrier for bisphosphonates due to the favourable biocompatibility and lower toxicity of the lipids compared with many polymers. The delivery platform consisted of a biomimetic α-tricalcium phosphate-gelatin cement (CPC) enriched with alendronate loaded MPs (MPs-AL) produced by the spray congealing technology...
October 3, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28983705/comparative-adherence-to-weekly-oral-and-quarterly-intravenous-bisphosphonates-among-patients-with-limited-heath-literacy-who-sustained-distal-radius-fractures
#5
Young Hak Roh, Jung Ho Noh, Hyun Sik Gong, Goo Hyun Baek
Individuals with limited health literacy (HL) are less likely to obtain preventive care. We designed a study to compare adherence to weekly oral and quarterly intravenous bisphosphonates among patients with low HL. The study enrolled a total of 432 female patients who presented with a distal radius fracture caused by low-energy trauma. Participant HL was measured using the Newest Vital Sign tool, and patients were randomized to weekly oral or quarterly intravenous bisphosphonate groups. Subjects in the intravenous bisphosphonate group received intravenous injections of 3 mg ibandronate every 3 months, and those in the oral bisphosphonate group self-administered 70 mg alendronate orally once each week for 12 months...
October 5, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/28941179/2017-american-college-of-rheumatology-guideline-for-the-prevention-and-treatment-of-glucocorticoid-induced-osteoporosis
#6
Lenore Buckley, Gordon Guyatt, Howard Fink, Timothy McAlindon
The Voting Panel recommended oral bisphosphonates as a first choice and parenteral bisphosphonates as a second choice after comparing data about absolute fracture reduction, harms (toxicity and inconvenience of daily injections), and costs. Drs. Maricic, Deal, Dore, and Laster cite the randomized trial of alendronate versus teriparatide in glucocorticoid-treated patients that reported incident fractures as a secondary outcome. This trial found a lower risk of clinical vertebral fractures in the teriparatide compared to alendronate treated patients (0% vs...
September 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28940569/weekly-oral-bisphosphonates-over-two-years-prevent-bone-loss-in-cardiac-transplant-patients
#7
Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter
BACKGROUND: Heart transplantation (HTX) is an established therapy for end-stage heart disease. The aim of this study was to determine whether application of oral bisphosphonates is effective in preventing osseous complications after HTX. METHODS: Thirty-three cardiac transplant recipients were treated with alendronate 70 mg/week or risedronate 35 mg/week in combination with 1000 mg calcium and 800 IU vitamin D. Markers of bone metabolism and dual energy X-ray absorptiometry (DXA) were determined directly after HTX and 2 years later...
September 23, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28938420/bone-structural-characteristics-and-response-to-bisphosphonate-treatment-in-children-with-hajdu-cheney-syndrome
#8
Sophia Sakka, Rachel I Gafni, Justin H Davies, Bart Clarke, Peter Tebben, Mark Samuels, Vrinda Saraff, Klaus Klaushofer, Nadja Fratzl-Zelman, Paul Roschger, Frank Rauch, Wolfgang Högler
Context: Hajdu-Cheney syndrome (HJCYS) is a rare, multisystem, bone disease caused by heterozygous mutations in the NOTCH2 gene. Histomorphometric and bone ultrastructural analyses in children have not been reported and sparse evidence exists on response to bisphosphonate (BP) therapy. Objective: To investigate clinical and bone histomorphometric characteristics, bone matrix mineralization and the response of bone geometry and density to BP therapy. Patients: Five children with HJCYS (3 males) aged between 6...
September 8, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28936581/exploring-methods-for-comparing-the-real-world-effectiveness-of-treatments-for-osteoporosis-adjusted-direct-comparisons-versus-using-patients-as-their-own-control
#9
Linda Karlsson, Johan Mesterton, Maurille Feudjo Tepie, Michele Intorcia, Jetty Overbeek, Oskar Ström
Using Swedish and Dutch registry data for women initiating bisphosphonates, we evaluated two methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for differences in patient baseline characteristics. Each method has advantages and disadvantages; both are potential complements to clinical trial analyses. PURPOSE: We evaluated methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for both observed and unobserved confounding...
September 21, 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28933038/methodological-considerations-for-comparison-of-brand-versus-generic-versus-authorized-generic-adverse-event-reports-in-the-us-food-and-drug-administration-adverse-event-reporting-system-faers
#10
Md Motiur Rahman, Yasser Alatawi, Ning Cheng, Jingjing Qian, Peggy L Peissig, Richard L Berg, David C Page, Richard A Hansen
BACKGROUND: The US Food and Drug Administration Adverse Event Reporting System (FAERS), a post-marketing safety database, can be used to differentiate brand versus generic safety signals. OBJECTIVE: To explore the methods for identifying and analyzing brand versus generic adverse event (AE) reports. METHODS: Public release FAERS data from January 2004 to March 2015 were analyzed using alendronate and carbamazepine as examples. Reports were classified as brand, generic, and authorized generic (AG)...
September 20, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28931828/a-novel-h2s-releasing-amino-bisphosphonate-which-combines-bone-anti-catabolic-and-anabolic-functions
#11
Simona Rapposelli, Laura Gambari, Maria Digiacomo, Valentina Citi, Gina Lisignoli, Cristina Manferdini, Vincenzo Calderone, Francesco Grassi
Bisphosphonates (BPs) are the first-line treatment of bone loss resulting from various pathological conditions. Due to their high affinity to bone they have been used to develop conjugates with pro-anabolic or anti-catabolic drugs. We recently demontrated that hydrogen sulfide (H2S), promotes osteogenesis and inhibits osteoclast differentiation. Here we developed an innovative molecule, named DM-22, obtained from the combination of alendronate (AL) and the H2S-releasing moiety aryl-isothiocyanate. DM-22 and AL were assayed in vitro in the concentration range 1-33 μM for effects on viability and function of human osteoclasts (h-OCs) and mesenchymal stromal cells (h-MSCs) undergoing osteogenic differentiation...
September 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28919430/role-of-subchondral-bone-properties-and-changes-in-development-of-load-induced-osteoarthritis-in-mice
#12
O O Adebayo, F C Ko, P T Wan, S R Goldring, M B Goldring, T M Wright, M C H van der Meulen
OBJECTIVE: Animal models recapitulating post-traumatic osteoarthritis (OA) suggest that subchondral bone (SCB) properties and remodeling may play major roles in disease initiation and progression. Thus, we investigated the role of SCB properties and its effects on load-induced OA progression by applying a tibial loading model on two distinct mouse strains treated with alendronate (ALN). DESIGN: Cyclic compression was applied to the left tibia of 26-week-old male C57Bl/6 (B6, low bone mass) and FVB (high bone mass) mice...
September 14, 2017: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/28903124/early-monitoring-of-osteoporosis-treatment-response-by-technetium-99m-methylene-diphosphonate-bone-scan
#13
Jingjing Lou, Guanghua Wen, Ke Dong, Yifan Zhang
OBJECTIVE: The aim of this study was to investigate the effectiveness of a technetium-99m-methylene diphosphonate (Tc-MDP) bone scan and the bone mineral density (BMD) test in monitoring the efficacy of osteoporosis (OP) treatment. PATIENTS AND METHODS: A total of 50 women with OP were prospectively enrolled in this study from January 2011 to October 2016 in our hospital. All the patients underwent a Tc-MDP whole-body bone scan and the BMD test before and after alendronate sodium treatment at 3, 6, 12 and 18 months, respectively...
October 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28892457/romosozumab-or-alendronate-for-fracture-prevention-in-women-with-osteoporosis
#14
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer
Background Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. Methods We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients)...
October 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28890795/bilateral-patellar-fractures-and-increased-cortical-bone-thickness-associated-with-long-term-oral-alendronate-treatment-in-a-cat
#15
Nicola Council, Jon Dyce, Wm Tod Drost, Joao Felipe de Brito Galvao, Thomas J Rosol, Dennis J Chew
CASE SUMMARY: A 14-year-old cat presented with bilateral patellar fractures and radiographically thickened tibial cortices. This cat had been treated with alendronate for 8 years prior to presentation. To remove the subjectivity of the radiographic evaluation, tibial radiographs from 35 apparently healthy geriatric cats were used for comparison. Cortical and diaphyseal thickness were measured at the proximal and distal thirds of the tibia. Our cat had increased cortical bone thickness compared to that of the control cats...
July 2017: JFMS open reports
https://www.readbyqxmd.com/read/28890137/secular-trends-of-use-of-anti-osteoporotic-treatments-in-spain-a-population-based-cohort-study-including-over-1-5million-people-and-more-than-12years-of-follow-up
#16
Elisa Martín-Merino, Consuelo Huerta-Álvarez, Daniel Prieto-Alhambra, Arturo Álvarez-Gutiérrez, Dolores Montero-Corominas
OBJECTIVE: Different regulatory actions for anti-osteoporotic medication (AOM) were taken during the last years, including marketing of new drugs, safety warnings, or restrictions on the indications. We aimed to characterise the secular trends of AOM use in Spain from 2001 to 2013. METHODS: A cohort study using the Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP), was performed. BIFAP includes anonym records for 4million patients. Participants entered the study when aged ≥50years in 2001-2013 and after 1year of data available, and were followed to an AOM prescription (including alendronate, other bisphosphonates, SERM (selective estrogen receptor modulators), strontium ranelate, teriparatide or denosumab), death, lost or the end of December 2013...
September 8, 2017: Bone
https://www.readbyqxmd.com/read/28878388/promotion-effect-of-extracts-from-plastrum-testudinis-on-alendronate-against-glucocorticoid-induced-osteoporosis-in-rat-spine
#17
Hui Ren, Gengyang Shen, Jingjing Tang, Ting Qiu, Zhida Zhang, Wenhua Zhao, Xiang Yu, Jinjing Huang, De Liang, Zhensong Yao, Zhidong Yang, Xiaobing Jiang
Alendronate (ALN) is a key therapeutic used to treat glucocorticoid-induced osteoporosis (GIOP), but may induce severe side effects. We showed earlier that plastrum testudinis extracts (PTE) prevented and treated GIOP in vivo. However, clinically, PTE is seldom used alone. Herein, we reveal the synergistic effect of ALN and PTE can treat GIOP of the rat spine and define the mechanism. Sprague-Dawley rats were randomly assigned to four groups: a vehicle group, a GIOP group, an ALN group, and an ALN+PTE group...
September 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28875236/bisphosphonate-drug-holidays-in-postmenopausal-osteoporosis-effect-on-clinical-fracture-risk
#18
M A Mignot, N Taisne, I Legroux, B Cortet, J Paccou
A cohort of 183 postmenopausal women, who had either discontinued or continued bisphosphonates (BPs) after first-line therapy, was used to investigate the relationships between "drug holiday" and clinical fracture. The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday." INTRODUCTION: BPs are the most widely used treatment for postmenopausal osteoporosis. The optimal treatment duration, however, remains unclear. The purpose of this study was to evaluate the fracture risk in postmenopausal women with osteoporosis after discontinuing BP treatment (BP "drug holiday")...
September 5, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28865182/quercetin-and-alendronate-multi-functionalized-materials-as-tools-to-hinder-oxidative-stress-damage
#19
Lucia Forte, Paola Torricelli, Elisa Boanini, Katia Rubini, Milena Fini, Adriana Bigi
In spite of its remarkable anti-oxidant, anti-inflammatory, anti-cancer properties and its possible inhibition activity towards bone resorption, quercetin therapeutic use is limited by its poor bioavailability. Herein we developed a new multifunctionalized system for the local administration of quercetin and alendronate, one of the most potent anti-osteoporotic drugs, with the aim to get a material with enhanced properties. To this purpose we loaded quercetin on hydroxyapatite functionalized with alendronate (HAAL), as well as on hydroxyapatite (HA)...
September 2, 2017: Journal of Biomedical Materials Research. Part A
https://www.readbyqxmd.com/read/28860420/baseline-mineralizing-surface-determines-the-magnitude-of-the-bisphosphonate-effect-on-cortical-bone-mineralization-in-postmenopausal-osteoporotic-patients
#20
B M Misof, S Blouin, S Lueger, E P Paschalis, R R Recker, R Phipps, K Klaushofer, P Roschger
PURPOSE: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). METHODS: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study...
September 1, 2017: Journal of Musculoskeletal & Neuronal Interactions
keyword
keyword
27344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"